Trials and Guidelines Flashcards
Name 3 guidelines that give recommendations on carotid stenting vs. endarterectomy. How are they the same? How do they differ?
- AHA/ACC
- SVS
- ESC
Same: All state that CAS is preferred for symptomatic patients >70% who are anatomically or otherwise high risk for surgery
Differ: AHA/ACC states CAS is an alternative to CEA for symptomatic patients > 70% in centers with stroke/death rates of < 6%. SVS and ESC state CEA is preferred in these patients.
*Name 8 trials comparing carotid stenting and endarterectomy and their conclusion with respect to inferiority of CAS
1) Leicester 1998: inferior
2. CAVATAS 2001: no difference
3. SAPPHIRE 2004/8: no difference
4. EVA-3S: inferior
5. SPACE 2006/8: no difference
6. Wallstent 2005: inferior
7. ICSS: Inferior 120d, no difference long term
8. CREST: no difference long term. periprocedural stroke superior. periprocedural MI inferior
*Describe ICSS trial
CAS vs CEA
Pts: >1700, over 50% symptomatic carotid stenosis
Findings: 30 d risk of stroke was 2x with CAS (7 vs 3%)
4 y risk of nondisabling stroke higher with CAS (15 vs 9%)
No difference in long term disabling stroke.
*Describe the SPACE trial
CAS vs CEA
Pts: 1200, > 70% symptomatic carotid stenosis
CEA and CAS no difference in stroke rate or death at 30d or 2y
Criticism: EPD only 27%
*Describe the EVA 3S trial
CAS vs CEA
Pts: >500 pateintes, > 60% symptomatic carotid stenosis
CAS had significantly worse stroke/death
30 d: 9.6 vs 3.9
6 mo: 11.7 vs 6%
Stopped early due to high death rate in CAS
Criticism: operator heterogeneity
*Describe the CREST trial
CAS vs CEA
Pts: 2500 symptomatic or asymptomatic > 70% stenosis with DUS or symptomatic >50% on angio
Roughly half were symptomatic and half were asymptomatic
No difference in stroke/MI/death or ipsilateral stroke
4 y: 7.2% vs 6.8%
10 y 11.8% vs 9.9%
CAS higher periprocedural stroke 4.1% vs 2.3%
CEA higher periprocedural MI 1.1% vs 2.3%
Which trials showed worse results with CAS compared with CEA?
- Leciester - CAS higher stroke rate
- EVA-3S no difference in end point but higher restenosis rate
- Wallstent
- ICSS : 30d risk of stroke 2x with CAS, long term disabling stroke no difference
Which trials comparing CAS and CEA have reported long term outcomes (10 y, 5 y)
10 y - CREST
5 y - ACT-1
(these are the only 2 listed on pg. 1231)